CPC A61K 51/0491 (2013.01) [A61K 51/12 (2013.01); A61P 35/00 (2018.01); C12N 15/113 (2013.01); C12N 15/115 (2013.01); B82Y 5/00 (2013.01); C12N 2310/11 (2013.01); C12N 2310/113 (2013.01); C12N 2310/122 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2310/16 (2013.01); C12N 2310/3517 (2013.01); C12N 2310/3519 (2013.01); C12N 2310/52 (2013.01)] | 26 Claims |
1. A method of diagnosing cancer in a subject, the method comprising administering to the subject an RNA dendrimer molecule, wherein the RNA dendrimer molecule comprises (a) a central core multi-branched RNA junction motif, wherein the central core motif comprises a plurality of branches, wherein a branch comprises at least one RNA oligonucleotide, and wherein the central core motif comprises at least one RNA oligonucleotide having at least 90% identity to SEQ ID NO: 12 (SquareE); and (b) an outer surface multi-branched RNA junction motif comprising at least one repeating multi-branched RNA junction motif unit, wherein the repeating unit comprises a plurality of branches, and wherein a branch comprises at least one RNA oligonucleotide, wherein the RNA dendrimer molecule comprises at least one imaging module, wherein the RNA dendrimer molecule comprises a folate receptor targeting module, wherein the cancer comprises a cancer that overexpresses folate receptor, and diagnosing the subject as having cancer if the RNA dendrimer molecule is detected in the subject.
|